Increased dietary consumption of docosahexaenoic acid (DHA) is associated with decreased risk for Alzheimer's disease (AD). These effects have been postulated to arise from DHA's pleiotropic effects on AD pathophysiology, including its effects on β-amyloid (Aβ) production, aggregation, and toxicity. While in vitro studies suggest that DHA may inhibit and reverse the formation of toxic Aβ oligomers, it remains uncertain whether these mechanisms operate in vivo at the physiological concentrations of DHA attainable through dietary supplementation. We sought to clarify the effects of dietary DHA supplementation on Aβ indices in a transgenic APP/PS1 rat model of AD. Animals maintained on a DHA-supplemented diet exhibited reductions in hippocampal Aβ plaque density and modest improvements on behavioral testing relative to those maintained on a DHA-depleted diet. However, DHA supplementation also increased overall soluble Aβ oligomer levels in the hippocampus. Further quantification of specific conformational populations of Aβ oligomers indicated that DHA supplementation increased fibrillar (i.e. putatively less toxic) Aβ oligomers and decreased prefibrillar (i.e. putatively more toxic) Aβ oligomers. These results provide in vivo evidence suggesting that DHA can modulate Aβ aggregation by stabilizing soluble fibrillar Aβ oligomers and thus reduce the formation of both Aβ plaques and prefibrillar Aβ oligomers. However, since fibrillar Aβ oligomers still retain inherent neurotoxicity, DHA may need to be combined with other interventions that can additionally reduce fibrillar Aβ oligomer levels for more effective prevention of AD in clinical settings.
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Introduction
Docosahexaenoic acid (DHA) is an ω-3 fatty acid that is an important structural component of cell membranes in the brain. Humans synthesize only a small fraction of their DHA requirements, with the remainder obtained from dietary sources, primarily fish oils. Dietary DHA consumption appears to be associated with Alzheimer's disease (AD) risk. Epidemiological studies have demonstrated that increased fish consumption correlates with decreased prevalence of AD and dementia, and that increased blood DHA levels correlate with slower cognitive decline (Cole et al., 2009) . While clinical trials examining the effects of DHA supplementation in AD dementia have not demonstrated clear benefits in mild-to-moderate AD dementia (Freund-Levi et al., 2006; Quinn et al., 2010) , other smaller studies have shown that fish oil or DHA supplementation improves cognition in mild cognitive impairment (Chiu et al., 2008; Kotani et al., 2006; Lee et al., 2013; Rondanelli et al., 2012; Sinn et al., 2012) and age-associated memory impairment (Vakhapova et al., 2010; Yurko-Mauro et al., 2010) . These findings suggest that DHA supplementation may be most beneficial at earlier stages of AD pathogenesis and more effective for the prevention of AD than its treatment.
The exact mechanisms that underlie the beneficial effects of DHA supplementation in AD remain somewhat uncertain (see Bazinet and Laye, 2014 for review). Studies in animal models suggest that DHA is likely to exert pleiotropic effects on AD pathology that help ameliorate associated behavioral deficits (Cole et al., 2009 ). Of particular interest, given prior work indicating that β-amyloid (Αβ) pathology is often Neurobiology of Disease 82 (2015) 552-560 
